The 2025 BIO Asia-Taiwan Exhibition has begun, with the Southern Taiwan Science Park Administration (STSPA) collaborating ...

In this week’s edition of The Prototype, we look at a quantum computing milestone for biotech, a new way to get forever ...

IIOVA stock is breaking out hard. We see a classic bullish continuation pattern coming out of consolidation, and momentum ...

Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Squawk Box' to discuss the troubles facing Sarepta and its ...

A new movie about OpenAI has cast the role of Elon Musk. While Musk could probably care less if you watch that movie that ...

Shopify's moat and vast runway for growth make its prospects highly attractive. Axsome Therapeutics has a robust late-stage pipeline that should lead to important approvals. Others understand that the ...

Key Points Sarepta Therapeutics' most crucial product is turning out to have severe safety issues. The company's efforts to improve its situation were well received, but this victory didn't last long.

A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand. | A brief skirmish between ...

A House subcommittee will hold a hearing today covering safety lapses and improvements to be made to the organ donor system. In other news: the FDA's debate on antidepressant use during pregnancy; the ...

Sarepta Therapeutics said it will voluntarily “and temporarily” pause all shipments of Elevidys® (delandistrogene ...